Biotech startup EPhysBio recently marked its one-year anniversary at URI. It is the second private-public partnership the Ryan Institute has helped to foster at URI, establishing a new drug discovery model in Rhode Island.
Continue reading "Spotlight on EPhysBio in ConvergenceRI"College students without ADHD are increasingly using them as “study drugs” in the hopes of boosting memory and learning. A new study looks at the trend.
Continue reading "Prescription “Study Drugs” Do Not Improve Cognition in Students Without ADHD"
Hermann Professor of Neuroscience William Van Nostrand receives $3 million grant to study cerebral amyloid angiopathy biomarkers.
Continue reading "$3 million CAA grant"
MindImmune Therapeutics, Inc., a biotech startup based at URI in affiliation with the Ryan Institute, recently acquired licensing for two research programs: a first-in-kind Huntington’s drug and a non-opioid painkiller for neuropathic pain.
Continue reading "MindImmune Receives Licensing for New Research"